Veradermics is a medical dermatology company focused on developing innovative therapeutics to address significant treatment challenges in dermatology. Founded by dermatologists, the company has established a diverse pipeline of first-in-class drug candidates targeting prevalent dermatological conditions such as androgenetic alopecia (pattern hair loss), common warts, alopecia areata, molluscum contagiosum, and atopic dermatitis. Their lead product candidate, VDPHL, is a novel, non-hormonal oral treatment designed for pattern hair loss, showcasing the company's commitment to advancing effective solutions for patients.

The pipeline includes five distinct product candidates, each aimed at addressing large-market dermatological conditions that have been underserved by current treatment options. These candidates utilize various mechanisms of action and delivery methods, such as immunotherapy and topical treatments. For instance, VDMN targets common warts through a dissolvable microarray delivery system, while VDAD is a novel oral immunomodulator for atopic dermatitis. Veradermics' approach emphasizes leveraging the clinical expertise of its board-certified dermatologists to create therapeutics that meet real-world patient needs in the dermatology field.

United States

Veradermics, Inc. is a medical dermatology company advancing first-in-class therapeutics that address real-world patient needs in under-innovated dermatology markets.

Veradermics

Company Details